Cogent Biosciences
COGT
25 hedge funds and large institutions have $3.75M invested in Cogent Biosciences in 2020 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 7 reducing their positions, and 8 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.49% less ownership
Funds ownership: 7.92% → 7.43% (-0.49%)
7% less funds holding
Funds holding: 27 → 25 (-2)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
46% less capital invested
Capital invested by funds: $6.99M → $3.75M (-$3.25M)
86% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$13.4K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$6.84K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$5.89K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$1.76K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$61 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$106K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$97K |
| 3 |
Renaissance Technologies
New York
|
-$63.1K |
| 4 |
Morgan Stanley
New York
|
-$62K |
| 5 |
Millennium Management
New York
|
-$34.4K |
COGT Hedge Fund Activity: Q1 2020 in Review
25 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q1 2020, worth a combined $3.75M — down 46% from $6.99M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of COGT and 6 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 1 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $13.4K. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $106K sold.
- 25 institutional investors held Cogent Biosciences (COGT) as of Q1 2020, down from 27 in Q4 2019.
- Funds reported $3.75M of Cogent Biosciences stock for Q1 2020, down 46% quarter-over-quarter.
- 6 funds opened new Cogent Biosciences positions in Q1 2020 and 8 closed out, a net change of -2 holders.
- The largest Cogent Biosciences buyer in Q1 2020 was Citadel Advisors, an estimated $13.4K added.
- The largest Cogent Biosciences seller in Q1 2020 was Sectoral Asset Management, an estimated $106K sold.
Based on aggregated 13F filings for Q1 2020.